SEC Tracker
Get the app

NewGenIvf Group NIVF

NewGenIvf reports Q2 2026 loss

Foreign issuer report

Form
6-K
Filed
Importance
Routine
  1. Net loss of $8.1M for six months ended June 30, 2026
  2. Revenue dropped to $1.9M from $2.0M in same period 2025
  3. Operating loss of $3.5M in six months ended June 30, 2026
  4. Share count adjusted due to multiple reverse splits in 2026

Written from the 6-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when NewGenIvf Group files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8090 and related industry codes: the same peer list as the financial tables.

  1. agilon health AGL public float $709M, Jun 30, 2025
  2. BioRestorative Therapies BRTX public float $11M, Jun 30, 2025
  3. Cryo Cell International CCEL public float $27M, May 31, 2025
  4. Chungui International BioTech Group CQFT
  5. Davita DVA public float $10.6B, Jun 30, 2025